

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 00/37113 (51) International Patent Classification 6: (11) International Publication Number: A61K 48/00, C07H 21/02, C12N 5/00, 29 June 2000 (29.06.00) (43) International Publication Date: (81) Designated States: JP, European patent (AT, BE, CH, CY, DB, PCTYUS99/30522 (21) International Application Number: DK. ES, FL FR, GB, GR, IE, TT, LU. MC, NL, PT, SE). (22) International Filing Date: 22 December 1999 (22.12.99) **Published** With international search report. (30) Priority Data: Before the expiration of the time limit for amending the 22 December 1998 (22.12.98) US 09/218,467 claims and to be republished in the event of the receipt of (71) Applicant: SMITHKLINE BEECHAM CORPORATION [US/US]; One Pranklin Plaza, Philadelphia, PA 19103 (72) Inventors: SATHE, Ganesh; 107 Hunters Run Road, King of Prussia, PA 19406 (US). ELLIS, Catherine, E.; 831 Fordhern Place, Glassboro, NJ 08028 (US). HALSEY. Wendy: 435 Bayard Road, Kenneth Square, PA 19348 (US). BEROSMA, Derk 271 Irish Road, Berwyn, PA 19312 (US). (74) Agents: ANDERSEN, Robert, L et al.; Retner & Prestia, 301 One Westlakes (Berwyn), P.O. Box 980, Valley Porge, PA 19482-0980 (US).

(54) Title: 11 CBY GENOMIC SEQUENCE

(57) Abstract

The present invention relates to 11 cby, in particular 11 cby polypeptides and 11 cby polypeptides, recombinant materials and methods for their production. In another expect, the invention relates to methods for using such polypeptides and polymedectides, including the treatment of bacterial, fungal, protocom and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; freeling and drinking abnormalities, such as ancrexia and bulimis; astituna; Parkinson's disease; both acute and congestive heart failure; hypertension; hypertension; unleasy stended, sending acutery, sending prostatic hypertrophy and psychods and neurological disorders, including acutery, schlzophrenia, manic depression, delirium, dementia or severe meatal retardation, and dyskinesias, such as Huntington's disease or Giltes de la Toureu's syndrome, hereinafter referred to as "the Diseases", amongst others. In a still further aspect, the invention relates to diagnostic and prognostic assays for denoting diseases associated with inappropriate 11 cby activity or levels. A method of performing genetic association studies for searching a disease susceptibility and/or drug response genes comprising using polymorphic markers in 11 cby polymelectides. Yet in further aspect, the invention relates to transgenic animals for disease models to screening for therapeutic.